Clal Biotechnology | CBI - Ebit


Clal Biotechnology reported ILS-5.44M in EBIT for its fiscal quarter ending in December of 2022.





Ebit Change Date
Arca Biopharma USD -25.09M 5.23M Mar/2025
aTyr Pharma USD -226.49K 140.85K Sep/2025
Bio Path USD -3.24M 616K Mar/2025
Brainstorm Cell Therapeutics USD -3.09M 100K Mar/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -7.89M 536K Sep/2025
Immunic USD -22.81M 756K Jun/2024
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
RedHill Biopharma USD 2.69M 47.97M Jun/2023
TherapeuticsMD USD -1.77M 699K Sep/2023